Wall Street brokerages expect KemPharm, Inc. (NASDAQ:KMPH) to report ($0.70) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for KemPharm’s earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.68). KemPharm reported earnings of ($0.68) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 2.9%. The firm is scheduled to announce its next earnings results on Thursday, March 8th.

According to Zacks, analysts expect that KemPharm will report full year earnings of ($2.67) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.64). For the next year, analysts anticipate that the firm will report earnings of ($2.60) per share, with EPS estimates ranging from ($2.65) to ($2.54). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover KemPharm.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.01.

Several research analysts have commented on the company. Royal Bank of Canada set a $9.00 price target on KemPharm and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $8.35.

Shares of KemPharm (NASDAQ:KMPH) traded up $0.15 during midday trading on Friday, reaching $5.10. The company’s stock had a trading volume of 60,200 shares, compared to its average volume of 81,391. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of -1.92. The company has a market cap of $74.75 and a P/E ratio of -1.75. KemPharm has a 52 week low of $2.45 and a 52 week high of $5.40.

In other KemPharm news, EVP Daniel L. Cohen purchased 7,500 shares of the company’s stock in a transaction on Monday, November 27th. The shares were bought at an average cost of $3.79 per share, with a total value of $28,425.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 25.40% of the company’s stock.

A hedge fund recently raised its stake in KemPharm stock. C WorldWide Group Holding A S increased its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 14.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 435,528 shares of the specialty pharmaceutical company’s stock after purchasing an additional 53,829 shares during the period. C WorldWide Group Holding A S owned about 2.97% of KemPharm worth $1,611,000 at the end of the most recent reporting period. 36.04% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “” was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/17/1054765.html.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit